Zhang Bo, Hu Yu, Pang Zhiqing
School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, China.
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Pharmacol. 2017 Dec 22;8:952. doi: 10.3389/fphar.2017.00952. eCollection 2017.
Nanomedicines including liposomes, micelles, and nanoparticles based on the enhanced permeability and retention (EPR) effect have become the mainstream for tumor treatment owing to their superiority over conventional anticancer agents. Advanced design of nanomedicine including active targeting nanomedicine, tumor-responsive nanomedicine, and optimization of physicochemical properties to enable highly effective delivery of nanomedicine to tumors has further improved their therapeutic benefits. However, these strategies still could not conquer the delivery barriers of a tumor microenvironment such as heterogeneous blood flow, dense extracellular matrix, abundant stroma cells, and high interstitial fluid pressure, which severely impaired vascular transport of nanomedicines, hindered their effective extravasation, and impeded their interstitial transport to realize uniform distribution inside tumors. Therefore, modulation of tumor microenvironment has now emerged as an important strategy to improve nanomedicine delivery to tumors. Here, we review the existing strategies and approaches for tumor microenvironment modulation to improve tumor perfusion for helping more nanomedicines to reach the tumor site, to facilitate nanomedicine extravasation for enhancing transvascular transport, and to improve interstitial transport for optimizing the distribution of nanomedicines. These strategies may provide an avenue for the development of new combination chemotherapeutic regimens and reassessment of previously suboptimal agents.
包括脂质体、胶束和基于增强渗透与滞留(EPR)效应的纳米颗粒在内的纳米药物,因其相较于传统抗癌药物的优越性,已成为肿瘤治疗的主流。纳米药物的先进设计,包括主动靶向纳米药物、肿瘤响应性纳米药物以及对物理化学性质的优化,以实现纳米药物向肿瘤的高效递送,进一步提高了它们的治疗效果。然而,这些策略仍无法克服肿瘤微环境的递送障碍,如血流不均、致密的细胞外基质、丰富的基质细胞和高间质液压力,这些严重损害了纳米药物的血管运输,阻碍了它们的有效渗出,并妨碍了它们的间质运输,从而无法在肿瘤内部实现均匀分布。因此,调节肿瘤微环境现已成为改善纳米药物向肿瘤递送的重要策略。在此,我们综述了现有的调节肿瘤微环境的策略和方法,以改善肿瘤灌注,帮助更多纳米药物到达肿瘤部位,促进纳米药物渗出以增强跨血管运输,并改善间质运输以优化纳米药物的分布。这些策略可能为开发新的联合化疗方案和重新评估以前效果欠佳的药物提供一条途径。